Logo

Salix (Bausch Health) Signs an Exclusive License Agreement with Mitsubishi Tanabe for its MT-1303 (amiselimod)

Share this

Salix (Bausch Health) Signs an Exclusive License Agreement with Mitsubishi Tanabe for its MT-1303 (amiselimod)

Shots:

  • MTPC to receive upfront- development & regulatory milestones and royalties on sales. Bausch Health to get exclusive WW rights to develop & commercialize MT-1303 (Ex-Japan & few other countries in Asia) in all fields (Ex. neurology- rheumatology and certain rare dermatology diseases)
  • Bausch plans to initiate the development of MTPC’s MT-1303 (amiselimod) in ulcerative colitis. MTPC will utilize the clinical data conducted by Bausch for regulatory approval and further commercialize it in Japan and certain other countries
  • MT-1303 (amiselimod) targets sphingosine-1-phosphate (S1P) receptor to retain lymphocytes sequestered in the lymph nodes and is evaluated in clinical studies for multiple sclerosis- psoriasis- Crohn's disease and systemic lupus erythematosus across Europe & Japan

Ref: Mitsubishi Tanabe | Image: Financial Post

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions